Oleanolic Acid : The Foundational Pentacyclic Triterpenoid, Master of Hepatoprotection & Systemic Cellular Harmony

Oleanolic Acid is a naturally occurring pentacyclic triterpenoid compound widely distributed throughout the plant kingdom, representing one of the most extensively studied and therapeutically versatile phytochemicals in modern pharmacology. This multifaceted molecule, existing both as a free acid and as an aglycone precursor for triterpenoid saponins, operates through a sophisticated array of molecular mechanisms to confer hepatoprotective, anti-inflammatory, antioxidant, and anticancer effects. By modulating key cellular signaling pathways, including nuclear factor kappa-B, protein kinase B, and the Keap1/Nrf2/ARE antioxidant response, it orchestrates a systemic defense against oxidative stress, inflammation, and fibrotic degeneration. Its therapeutic potential, validated through decades of clinical use in Asia and increasingly recognized worldwide, positions it as a cornerstone compound for liver health and a promising candidate for addressing complex diseases ranging from metabolic disorders to neurodegeneration.

---

1. Overview:

Oleanolic acid (OA) is a pentacyclic triterpenoid compound with the chemical formula 3β-hydroxyolean-12-en-28-oic acid, found in more than 1,600 different plant species. It is one of the most common triterpenoids in nature, often coexisting with its structural isomer ursolic acid. Its primary biological actions are remarkably diverse, encompassing hepatoprotection, anti-inflammatory activity, antioxidant effects, anticancer properties, antimicrobial activity, and metabolic regulation. It exerts these effects through modulation of multiple cellular signaling pathways, including inhibition of nuclear factor kappa-B, activation of the Keap1/Nrf2/ARE antioxidant pathway, and regulation of apoptotic proteins such as Bcl-2 and Bax. Its ability to simultaneously address multiple pathological mechanisms makes it a compelling candidate for the prevention and treatment of complex, multifactorial diseases. It represents a foundational compound in the pharmacology of natural products, with a safety profile and efficacy that have led to its approval as an over-the-counter drug in China for the treatment of liver disorders.

2. Origin & Common Forms:

Oleanolic acid is widely distributed in the plant kingdom and is a common component of many foods, medicinal herbs, and traditional remedies.

· Standardized Oleanolic Acid Extracts: Purified extracts from source plants, typically standardized to a specific OA content. This is a common supplemental form.

· Olive-Derived Oleanolic Acid: Olives and olive leaves are among the richest sources, with OA being the most abundant triterpene in virgin olive oils. It is concentrated in the cuticle wax of the fruit and leaves.

· Fructus Ligustri Lucidi (Nuzhenzi) Extract: The fruit of Ligustrum lucidum, a traditional Chinese medicine, is a very rich source of OA and is widely used for its therapeutic properties.

· Other Plant Sources: Present in many common fruits including apples, loquats, grapes, and pomegranates, as well as in herbs such as rosemary, thyme, and lavender, and in the bark of trees like Eucalyptus globulus.

· Food-Based Sources: Dietary intake of OA comes primarily from olives and olive oil, as well as from fruits and herbs that contain the compound.

3. Common Supplemental Forms:

· Oleanolic Acid Capsules/Tablets: Typically providing 10 mg to 50 mg per serving for liver support, though doses for research and specialized applications may be higher.

· Oleanolic Acid Powder: For flexible dosing, often used in research settings.

· Blended Liver Health Formulas: Combined with other hepatoprotective agents like silymarin (milk thistle), schisandra, or ursodeoxycholic acid for comprehensive liver support.

· Pharmaceutical Preparations: In China, OA is available as an over-the-counter drug in tablet and capsule form (typically 10 mg to 20 mg) for the treatment of hepatitis.

4. Natural Origin:

· Primary Plant Sources: Olive (Olea europaea) fruits and leaves, Ligustrum lucidum (Fructus Ligustri Lucidi) fruits, Aralia elata (Japanese angelica tree) roots and stems, and various Viscum (mistletoe) species. It is also abundant in clove leaves, pomace, and blossoms.

· Biosynthesis: Plants synthesize oleanolic acid via the mevalonate (MVA) pathway. The key steps involve the cyclization of 2,3-oxidosqualene by β-amyrin synthase (β-AS) to form the β-amyrin skeleton, followed by oxidation steps catalyzed by cytochrome P450 enzymes to introduce the carboxyl group at the C-28 position, yielding oleanolic acid. Recent research has identified transcription factors such as AeMYB9 and AeMYB73 in Aralia elata that respond to methyl jasmonate and positively regulate OA biosynthesis by activating the expression of the Aeβ-AS gene.

5. Synthetic / Man-made:

· Process: Commercial production relies primarily on extraction from plant sources, though chemical synthesis and semi-synthesis are possible and used for producing specialized derivatives.

1. Harvesting & Extraction: Plant material rich in OA, such as Ligustrum lucidum fruits or olive processing byproducts, is harvested, dried, and extracted with organic solvents such as ethanol or methanol.

2. Purification: The crude extract undergoes purification through techniques such as column chromatography, crystallization, or acid-base fractionation to isolate OA from other triterpenoids and plant compounds.

3. Crystallization: Purified OA is crystallized to achieve a white to off-white crystalline powder of high purity.

4. Derivative Synthesis: For pharmaceutical applications, OA may be used as a starting material for semi-synthetic modifications to produce more potent derivatives, such as bardoxolone methyl (CDDO-methyl) and other 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) analogs.

6. Commercial Production:

· Precursors: Cultivated plant biomass, particularly from Ligustrum lucidum and olive processing byproducts. The olive industry provides a sustainable source of OA from waste streams.

· Process: Involves harvesting, drying, milling, solvent extraction, filtration, concentration, chromatographic purification or recrystallization, and drying. The process is optimized to achieve high purity and consistent yield.

· Purity & Efficacy: High-quality oleanolic acid is typically >90% to >98% pure, verified by HPLC. Efficacy is dose-dependent and has been validated through extensive preclinical and clinical research.

7. Key Considerations:

The Multitarget Natural Therapeutic. Oleanolic acid's primary distinction among natural compounds is its remarkable pleiotropic activity and its ability to simultaneously address multiple pathological mechanisms. Unlike single-target synthetic drugs, OA operates through a network of interconnected pathways, modulating inflammation, oxidative stress, apoptosis, and cellular metabolism in a coordinated manner. This multitarget profile is particularly valuable for complex, multifactorial diseases such as metabolic syndrome, neurodegenerative disorders, and cancer, where dysregulation of multiple pathways contributes to disease progression. Its hepatoprotective effects are so well-established that OA is an approved over-the-counter drug in China for the treatment of acute and chronic hepatitis. Furthermore, its role as a scaffold for semi-synthetic derivatives, particularly the CDDO series developed by Reata Pharmaceuticals, highlights its importance as a lead compound in modern drug discovery. These derivatives, which activate the Keap1/Nrf2/ARE antioxidant pathway with vastly greater potency than the parent molecule, have advanced to clinical trials for conditions such as chronic kidney disease and pulmonary arterial hypertension, demonstrating the translational potential of this ancient natural product.

8. Structural Similarity:

3β-Hydroxyolean-12-en-28-oic acid. A pentacyclic triterpenoid consisting of six isoprene units forming a structure with five fused rings (A, B, C, D, and E). It has the molecular formula C30H48O3 and a molecular weight of 456.7. Key structural features include a hydroxyl group at the C-3 position, a double bond between C-12 and C-13, and a carboxyl group at C-28. It is structurally very similar to its isomer ursolic acid, the only difference being the position of a methyl group on the E-ring. This lipophilic skeleton allows it to interact with cell membranes and bind to nuclear receptors, mimicking endogenous ligands.

9. Biofriendliness:

· Utilization: Orally absorbed, but with poor and variable bioavailability due to its hydrophobic nature and low water solubility. It is nearly insoluble in water, sparingly soluble in ethanol and acetone, and soluble in 1-butanol.

· Bioavailability Enhancement: Recent research has focused on improving the oral bioavailability of OA. A 2026 study demonstrated that a menthol-fatty acid-based hydrophobic deep eutectic solvent (HDES) system could increase the apparent in vitro bioavailability index of OA by 9.3-fold compared to conventional ethanol systems, with efficacy showing clear fatty acid chain-length dependence. This mechanism involves enhanced digestive release and cellular absorption through Caco-2 cell monolayers.

· Metabolism & Distribution: Absorbed OA is metabolized in the liver, primarily through phase I and phase II reactions, including oxidation, reduction, and conjugation with glucuronic acid. It is distributed to various tissues, including the liver, kidneys, and brain.

· Excretion: Metabolites are excreted primarily in urine and bile.

· Toxicity: Very low. OA has an excellent safety profile in animal studies and human clinical use. It is well-tolerated at therapeutic doses, with the only reported adverse effects being mild and gastrointestinal in nature. The LD50 is high, indicating a wide therapeutic window. In China, where it is an approved over-the-counter drug, the recommended doses for hepatitis (30 mg to 200 mg daily) are well below toxic levels.

10. Known Benefits (Clinically Supported):

· Hepatoprotection: The most well-documented and clinically used effect. OA significantly reduces serum alanine aminotransferase levels, attenuates liver injury induced by toxins such as carbon tetrachloride, alleviates liver fibrosis and cirrhosis, and induces apoptosis in liver cancer cells. It is approved in China for the treatment of acute and chronic hepatitis.

· Anti-inflammatory Activity: Potently inhibits the nuclear factor kappa-B (NF-κB) signaling pathway, reducing the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1, and interleukin-6. It also inhibits the expression of inflammatory enzymes including cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS).

· Antioxidant Effects: Activates the Keap1/Nrf2/ARE antioxidant response pathway, upregulating the expression of phase II detoxifying enzymes and antioxidant proteins such as heme oxygenase-1 (HO-1), glutathione S-transferases, and NAD(P)H quinone oxidoreductase. It also directly scavenges free radicals.

· Anticancer Activity: Inhibits proliferation, induces apoptosis, and suppresses metastasis and angiogenesis in various cancer types, including breast cancer, hepatocellular carcinoma, and non-small cell lung cancer. Its derivatives, such as SZC014, show enhanced cytotoxicity with greater selectivity for cancer cells over normal cells.

· Nephroprotective Effects: Protects against acute kidney injury and chronic kidney disease in various animal models, including renal ischemia-reperfusion injury, drug-induced nephrotoxicity, diabetic nephropathy, and renal fibrosis. Mechanisms involve anti-inflammatory, antioxidant, and anti-fibrotic effects, as well as enhancement of autophagy.

· Cardioprotective Effects: Prevents dexamethasone-induced hypertension, regulates prostacyclin release from coronary artery smooth muscle cells to maintain vascular homeostasis, and exhibits anti-atherosclerotic effects comparable to simvastatin in animal models.

· Neuroprotective Effects: Protects against cerebral ischemia-reperfusion injury, reduces brain infarction in stroke models, and improves chronic brain damage. Emerging evidence supports its potential in Alzheimer's disease by reducing β-amyloid aggregation and toxicity, inhibiting tau hyperphosphorylation, and attenuating neuroinflammation.

· Antidiabetic Effects: Improves blood glucose control, enhances insulin sensitivity, and protects against diabetic complications in animal models of diabetes. It acts as an agonist of peroxisome proliferator-activated receptor gamma (PPARγ) and modulates other metabolic nuclear receptors.

· Gastroprotective Effects: Promotes healing of chronic gastric ulcers, reduces lesion area, and increases mucosal thickness in animal models.

· Antimicrobial Activity: Exhibits antibacterial, antiviral, and antifungal properties. It enhances the activity of certain antibiotics like ampicillin and shows anti-HIV activity through inhibition of HIV-1 protease.

11. Purported Mechanisms:

· Activation of the Keap1/Nrf2/ARE Antioxidant Pathway: OA and its synthetic derivatives, particularly the CDDO series, are potent activators of this master cytoprotective pathway. By modifying critical cysteine residues in the Keap1 protein, they cause the release of Nrf2, which then translocates to the nucleus and binds to antioxidant response elements (ARE), driving the expression of over 200 cytoprotective genes, including antioxidant enzymes, phase II detoxifying enzymes, and anti-inflammatory proteins.

· Inhibition of Nuclear Factor kappa-B (NF-κB) Signaling: OA blocks the activation of NF-κB, a key transcription factor in inflammatory responses. It inhibits the phosphorylation and degradation of IκBα, preventing the nuclear translocation of p65 and suppressing the expression of pro-inflammatory genes such as COX-2, iNOS, TNF-α, and IL-6.

· Modulation of Apoptosis Pathways: OA induces apoptosis in cancer cells through both intrinsic (mitochondrial) and extrinsic (death receptor) pathways. It upregulates pro-apoptotic proteins such as Bax and Bak, downregulates anti-apoptotic proteins such as Bcl-2, and activates caspases 3, 8, and 9, leading to PARP cleavage and programmed cell death. Its derivative SZC015 increases the Bax/Bcl2 ratio and activates caspases 3 and 9.

· Cell Cycle Arrest: OA and its derivatives can arrest the cell cycle at various phases, including G1 phase arrest in breast cancer cells treated with SZC014, thereby inhibiting cancer cell proliferation.

· Inhibition of Metastasis and Angiogenesis: OA suppresses tumor metastasis by inhibiting the expression and activity of matrix metalloproteinases (MMPs) and reduces angiogenesis by inhibiting STAT3 and sonic hedgehog signaling pathways.

· Modulation of Metabolic Nuclear Receptors: OA acts as a ligand for several nuclear receptors involved in metabolism, including farnesoid X receptor (FXR), peroxisome proliferator-activated receptors (PPARα, PPARγ), liver X receptor (LXR), retinoid X receptor (RXR), pregnane X receptor (PXR), and retinoic acid receptor-related orphan receptors (ROR). Through these interactions, it exerts tissue-specific effects on bile acid metabolism, lipid homeostasis, glucose regulation, and inflammation, contributing to its hepatoprotective and anti-atherosclerotic effects.

· Inhibition of the PI3K/Akt/mTOR Pathway: OA suppresses this key survival pathway in cancer cells, reducing proliferation and promoting apoptosis.

· Activation of MAPK Signaling Pathways: OA can activate ERK, JNK, and p38 MAPK pathways, which can lead to either cell survival or apoptosis depending on cellular context and duration of activation.

· Anti-fibrotic Effects: OA inhibits the activation of hepatic stellate cells and reduces extracellular matrix deposition by downregulating TGF-β1 signaling and Smad2/3 phosphorylation, thereby attenuating liver and kidney fibrosis.

· Autophagy Enhancement: OA enhances autophagic flux, promoting the clearance of damaged organelles and protein aggregates, which contributes to its protective effects in neurodegenerative and kidney diseases.

· Reduction of β-amyloid Aggregation and Toxicity: In Alzheimer's disease models, OA and its saponin derivatives reduce Aβ-induced cytotoxicity, decrease APP expression, inhibit PSEN1 and PSEN2 (genes involved in γ-secretase activity), and reduce Aβ42 aggregation by up to 80%, thereby protecting neuronal cells from amyloid toxicity.

12. Other Possible Benefits Under Research:

· Osteoprotective Effects: OA derivatives, such as compound 143, have shown dual anabolic and anti-resorptive effects on bone, inhibiting osteoclast formation with high potency (IC50 0.098 μM) and stimulating new bone formation.

· Wound Healing: Promotes tissue regeneration and accelerates wound closure in animal models.

· Anti-aging Effects: Through activation of Nrf2 and modulation of cellular stress responses, OA may have potential in延缓 aging and age-related diseases.

· Treatment of Non-Alcoholic Steatohepatitis (NASH): OA shows promise in alleviating NASH and liver fibrosis through modulation of FXR and other nuclear receptors.

· Cholestatic Liver Injury: Attenuates alpha-naphthol isothiocyanate (ANIT)-induced cholestasis, with hepatoprotective properties comparable to ursodeoxycholic acid (UDCA) in bile duct ligation models.

· Atopic Dermatitis: Ameliorates atopic dermatitis by inhibiting Akt, NF-κB, and STAT1 signaling pathways.

· Antioxidant Inflammation Modulators: Patented derivatives (e.g., Reata Pharmaceuticals' compounds) are being developed for systemic use in oxidative stress-related diseases.

13. Side Effects:

· Minor & Transient (Likely No Worry):

· Gastrointestinal Upset: Dry mouth, diarrhea, or mild upper abdominal discomfort may occur in a small percentage of users, particularly at higher doses. These symptoms typically resolve with continued use or dose adjustment.

· Mild Platelet Reduction: Individual cases of mild, transient thrombocytopenia (reduced platelet count) have been reported, which resolve upon discontinuation.

· To Be Cautious About:

· Allergic Reactions: Rare hypersensitivity reactions may occur in susceptible individuals.

· Dose-Dependent Effects: While safe at therapeutic doses, the effects of very high, prolonged dosing have not been extensively studied in humans. The recommended therapeutic window for liver support (30-200 mg daily) should be respected.

14. Dosing & How to Take:

· Liver Support (Approved Clinical Use in China):

· Acute Hepatitis: 30 mg three times daily (90 mg total daily dose).

· Chronic Hepatitis: 50 mg four times daily (200 mg total daily dose). Treatment typically continues for three months as a course.

· General Health and Antioxidant Support: 25 mg to 100 mg daily, often divided into one or two doses.

· Research and Specialized Applications: Doses in clinical and preclinical studies vary widely, from 50 mg to over 500 mg daily, depending on the condition and formulation.

· How to Take:

· With Food: Taking OA with meals can enhance absorption and reduce the likelihood of gastrointestinal discomfort, given its lipophilic nature.

· With Lipids: Co-administration with dietary fats or oils may improve absorption due to its lipophilic character.

· Advanced Formulations: Newer formulations, such as the menthol-fatty acid HDES system, are under development to dramatically improve oral bioavailability.

· Consistency: Benefits for chronic conditions are most pronounced with consistent, long-term use.

15. Tips to Optimize Benefits:

· Synergistic Combinations:

· With Ursolic Acid: As OA often co-occurs with its isomer ursolic acid, and the two compounds have complementary and synergistic effects, full-spectrum extracts containing both may offer enhanced benefits.

· With Silymarin (Milk Thistle): For comprehensive liver support, combining OA with other hepatoprotective flavonoids may provide additive or synergistic effects.

· With Phosphatidylcholine or Lipids: Formulating OA with phospholipids or lipid-based delivery systems can significantly enhance its oral bioavailability.

· Advanced Delivery Systems: Look for products utilizing modern bioavailability enhancement technologies, such as hydrophobic deep eutectic solvents, phytosomes, or nanoformulations, which can increase absorption many-fold.

· Targeted Use for Specific Conditions: OA is most effective when used for defined indications, particularly liver support, metabolic health, or as part of an integrative approach to inflammatory conditions.

· Support Liver Health: Benefits are maximized by an overall healthy lifestyle that supports liver function, including adequate hydration, a nutrient-dense diet, limited alcohol consumption, and avoidance of hepatotoxic substances.

16. Not to Exceed / Warning / Interactions:

· Contraindications:

· Hypersensitivity: Contraindicated in individuals with known allergy to oleanolic acid or any components of the formulation.

· Drug Interactions (CAUTION):

· Anticoagulant/Antiplatelet Drugs: Theoretical risk of increased bleeding due to potential antiplatelet effects, though clinically significant interactions have not been well-documented. Use with caution in patients on warfarin, aspirin, or clopidogrel.

· Hepatotoxic Drugs: May have additive or protective effects when combined with drugs that affect the liver. Patients on medications with known hepatotoxicity should use OA only under medical supervision.

· Drugs Metabolized by CYP450 Enzymes: OA may modulate the activity of certain cytochrome P450 enzymes. Patients on medications with a narrow therapeutic index metabolized by these pathways should use caution.

· Antidiabetic Medications: May enhance glucose-lowering effects due to its PPARγ agonist activity. Monitor blood glucose if combining.

· Medical Conditions:

· Pregnancy and Lactation: Safety has not been established. While dietary intake from foods like olives is safe, high-dose supplementation should be avoided during pregnancy and breastfeeding.

· Liver Disease: While OA is used to treat liver disease, patients with severe hepatic impairment should use it only under medical supervision.

· Autoimmune Diseases: Due to its immunomodulatory effects, use with caution in individuals with autoimmune conditions.

17. LD50 & Safety:

· Acute Toxicity (LD50): Not established in humans, but animal studies demonstrate a very high LD50, indicating low acute toxicity. Rodent oral LD50 values are typically >2,000 mg/kg body weight.

· Human Safety: Oleanolic acid possesses an outstanding safety profile, supported by decades of clinical use in Asia as an approved over-the-counter drug for hepatitis. It is well-tolerated, non-mutagenic, and non-teratogenic in animal studies. The most common adverse effects are mild and gastrointestinal. Its wide therapeutic window and favorable safety profile make it one of the safest and most thoroughly vetted natural products for human use.

18. Consumer Guidance:

· Label Literacy: Look for "Oleanolic Acid," "Olean-12-en-28-oic acid, 3β-hydroxy," or "Oleanol" on the label. The source (e.g., from olive, Ligustrum lucidum) and standardization percentage should be clearly stated. The milligram amount per serving should be unambiguous.

· Quality Assurance: Choose reputable brands that provide third-party testing to verify the identity, purity, and concentration of the oleanolic acid content (typically by HPLC). Given the compound's hydrophobicity, formulations that address bioavailability are preferable.

· Regulatory Status: In China, OA is an approved over-the-counter drug for hepatitis. In the United States and Europe, it is generally available as a dietary supplement. It is not a controlled substance.

· Manage Expectations: Oleanolic acid is a clinically validated, multitarget natural therapeutic with a primary role in liver health and growing evidence for applications in metabolic, inflammatory, and neurodegenerative diseases. Its benefits are most pronounced with consistent, long-term use and when formulated for optimal bioavailability. It is not a quick-acting compound but a foundational agent for systemic cellular protection and resilience. Its role as the parent compound for advanced pharmaceutical derivatives, such as the CDDO series, underscores its significance as one of the most important and promising natural products in modern medicine.

-x-x